The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
 
Minsuk Kwon
No Relationships to Disclose
 
Bo Mi Ku
No Relationships to Disclose
 
Sehhoon Park
Stock and Other Ownership Interests - Lunit
 
Hyun Ae Jung
No Relationships to Disclose
 
Jong-Mu Sun
Research Funding - AstraZeneca/MedImmune (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst)
 
Se-Hoon Lee
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Novartis; Roche
Research Funding - Merck
Travel, Accommodations, Expenses - Novartis
 
Jin Seok Ahn
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb-Ono Pharmaceutical; Eisai; Janssen; Menarini; MSD; Pfizer; Roche
Consulting or Advisory Role - Samsung Bioepis
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Hanmi; Lilly; LOXO; Merck KGaA; MSD; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - AZD; Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Lilly; MSD; TAKEDA
Consulting or Advisory Role - Alpha pharmaceutical; AstraZeneca; Boehringer Ingelheim; Lilly; MSD; TAKEDA